Cortexyme, Inc.

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. -0.36%332.400.0%$4436.90m
BNTXBioNTech SE 2.10%268.360.0%$738.37m
NVAXNovavax, Inc. -15.78%135.2279.4%$598.89m
AMGNAmgen, Inc. 1.44%209.771.4%$554.21m
SNSSSunesis Pharmaceuticals, Inc. 4.64%6.430.7%$449.48m
REGNRegeneron Pharmaceuticals, Inc. 1.55%560.682.7%$438.28m
GILDGilead Sciences, Inc. 0.30%67.101.0%$414.29m
CCXIChemoCentryx, Inc. 3.17%34.722.9%$397.60m
ILMNIllumina, Inc. -0.22%413.163.3%$373.79m
XLRNAcceleron Pharma, Inc. -0.58%172.735.3%$348.29m
VRTXVertex Pharmaceuticals, Inc. 0.43%186.201.9%$270.91m
BIIBBiogen, Inc. -0.50%266.801.7%$242.32m
OCGNOcugen, Inc. 5.76%8.810.0%$186.58m
XENEXenon Pharmaceuticals, Inc. 2.15%30.450.4%$163.82m
CRSPCRISPR Therapeutics AG -1.76%98.500.6%$159.28m

Company Profile

Cortexyme, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics. Its pipeline comprises COR388, COR588, COR788, COR822, and Coronavirus 3CL protease inhibitor. The company was founded by Casey Crawford Lynch, Stephen Dominy, and Kristen Gafric on June 20, 2012 and is headquartered in South San Francisco, CA.